Aspects of practical application of ‘STOPP/START’ criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi‑speciality hospital

Introduction. Polypharmacy and the administration of potentially non-recommended drugs are the causes of adverse drug reactions. The absence of potentially recommended drugs leads to a decrease in the duration and quality of life, an increased risk of complications from various organs and systems.
The purpose of the study. To analyze the structure of prescribed drugs in patients over 65 years of age with atrial fibrillation (AF) and chronic kidney disease (CKD) stages 3 and 4 for the presence of рolypharmacy and compliance of prescriptions with the criteria STOPP/START.
Materials and methods. 125 case histories were analyzed in patients 65 years and older with AF and CKD. Patients were divided into two groups: group 1 – patients with AF and CKD 3a (n = 51; 84.3 % of women; mean age 86.1 ± 6.4 years; mean score on the CHA(2) DS(2)-VASc scale 6.2 ± 1.1 points; mean score on the HAS-BLED scale 3.00 ± 0.68 points); group 2 – patients with AF and CKD 3b and 4 stages (n = 39; 84.6 % of women; mean age 87.9 ± 4.7 years; mean score on the CHA(2) scale; DS(2)-VASc 6.1 ± 1.2 points; the average score on the HAS-BLED scale is 3.10 ± 0.71 points). All 100 % of patients in both groups had a high risk of stroke on the CHA(2) DS(2)-VASc scale (≥ 2 points for men; ≥ 3 points for women), 82.4 % of patients in group 1 and 79.5 % of patients in group 2 had a high risk of bleeding on the HAS-BLED scale (≥ 3 points). According to the prescribing sheets of medical histories, the frequency of polypharmacy was evaluated, as well as the structure of drug prescriptions according to the STOPP/START criteria.
Results. The number of patients who were prescribed ≥5 drugs was 100 % in group 1 and 94.9 % in group 2. The number of patients receiving ≥10 drugs at the same time was 11.8 % and 20.5 % in group 1 and 2, respectively. In 64.7 % of patients from group 1 and in 53.8 % of patients from group 2, potentially non-recommended but prescribed drugs (STOPP) are present in the prescribing lists. At the same time, 96.1 % and 100 % of patients in groups 1 and 2, respectively, were not prescribed drugs that are recommended for elderly patients (START criteria).
Conclusion. Patients with AF and CKD aged 65 years and older are often prescribed potentially non-recommended drugs that significantly reduce the quality of life and increase the risk of adverse drug reactions. These patients were also often not prescribed potentially recommended drugs that are necessary to improve the prognosis, reduce the risk of complications, and reduce the number of hospitalizations. The revealed facts dictate the need to optimize pharmacotherapy in elderly and senile patients with AF and CKD in a hospital setting.

1. Malkov P. V., Baranov E. F., Bezborodova T. S., Bobylev S. N., Bugakova N. S., Gokhberg L. M., Grigoriev L. M., Egorenko S. N., Elizarov V. V., Zhitkov V. B., Ivanov Yu.N., Kevesh A. L., Kosarev A. E., Laikam K. E., Maleva T M., Masakova I. D., Nesterov V. N., Oksenoit G. K., Rybak O. P., Ryabushkin B. T., Sabelnikova M. A., Tatarinov A. A., Khoroshilov A. V. Russia in Figures 2019. Brief Statistical Book. Moscow: Rosstat; 2018. 549 p. (In Russ.)

2. Menotti A., Mulder I., Nissinen A., Giampaoli S., Feskens E. J., Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol. 2001; 54 (7): 680–6. https://doi.org/10.1016/s0895–4356(00)00368–1

3. Cassell A., Edwards D., Harshfield A., Rhodes K., Brimicombe J., Payne R., Griffin S. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018; 68 (669): e245–e251. https://doi.org/10.3399/bjgp18X695465

4. Kurian J., Mathew J., Sowjanya K., Chaitanya K. R., Ramesh M., Sebastian J., Narayanappa D. Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study. Indian J Pediatr. 2016; 83 (5): 414–9. https://doi.org/10.1007/s12098–015–2002–1.

5. Sychev D. A. Polypharmacy in clinical practice: a problem and solutions. 2nd edition. St. Petersburg: CSC ‘Profession’; 2018. 272 p. (In Russ.)

6. Scott I., Jayathissa S. Quality of drug prescribing in older patients: is there a problem and can we improve it? Intern Med J. 2010; 40 (1):7–18. https://doi.org/10.1111/j.14455994.2009.02040.x.

7. Gnjidic D., Hilmer S. N., Blyth F. M., Naganathan V., Waite L., Seibel M. J., McLachlan A.J., Cumming R. G., Handelsman D. J., Le Couteur D. G. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012; 65 (9): 989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018

8. Joppi R., Cinconze E., Mezzalira L., Pase D., Poggiani C., Rossi E., Pengo V.; Italian Horizon Scanning Project. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med. 2013; 24 (4): 318–23. https://doi.org/10.1016/j.ejim.2013.02.018

9. LaMori J.C., Mody S. H., Gross H. J., daCosta DiBonaventura M., Patel A. A., Schein J. R., Nelson W. W. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013; 7 (2): 53–62. https://doi.org/10.1177/1753944712464101

10. Skov J., Bladbjerg E. M., Sidelmann J., Vamosi M., Jespersen J. Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic. Eur J Clin Pharmacol. 2011; 67 (11): 1169–1174. https://doi.org/10.1007/s00228–011–1045–0

11. Adeera L., Paul E. Stevens, Rudy W. Bilous, Coresh J., Angel L. M. De F., Paul E. De J., Kathryn E. Griffith, Brenda R. Hemmelgarn, Kunitoshi I., Edmund J. Lamb, Andrew S. Levey, Miguel C. Riella, Michael G. Shlipak, Haiyan Wang, Colin T. White, Christopher G. Winearls. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1–150. https://doi.org/10.1038/kisup.2012.48

12. Wang Y., Singh S., Bajorek B. Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation. Pharm Pract (Granada). 2016; 14 (2): 706. https://doi.org/10.18549/PharmPract.2016.02.706.

13. Rivkin V. L. Chronic constipation. Medical advice. 2013;(10):76–80. (In Russ.)

14. Ivashkin V. T., Mayev I. V., Sheptulin A. A., Trukhmanov A. S., Poluektova Y. A., Baranskaya Y. K., Shifrin O. S., Lapina T. L., Osipenko M. F., Simanenkov V. I., Khlynov I. B. Diagnostics and treatment of chronic constipation in adults: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (3): 75–83. (In Russ.) https://doi.org/10.22416/1382–4376–2017–27–3–75–83

15. Lazebnik L. B., Prilepskaya S. I., Baryshnikov E. N., Parfenov A. I., Kosacheva T. N. Prevalence and risk factors of constipation in the adult population of Moscow (according to the population study «MUZA». Experimental and clinical gastroenterology. 2011; (3): 68–73. (In Russ.)

16. Towers A. L., Burgio K. L., Locher J. L., Merkel I. S., Safaeian M., Wald A. Constipation in the elderly: influence of dietary, psychological, and physiological factors. J Am Geriatr Soc. 1994; 42 (7): 701–6. https://doi.org/10.1111/j.1532–5415.1994.tb06527.x

17. Drossman D. A., Li Z., Andruzzi E., Temple R. D., Talley N. J., Thompson W. G., Whitehead W. E., Janssens J., Funch-Jensen P., Corazziari E., Richter J. E., Koch G. G. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993; 38 (9): 1569–1580. https://doi.org/10.1007/BF01303162

18. Sychev D. A., Orekhov R. E. Anticholinergic load scale as a method of fighting polypharmacy in elderly and senile patients. Clinical pharmacology and therapy. 2016; 25 (4): 81–84. (In Russ.)

19. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020; 25 (11): 4076. (In Russ.) https://doi.org/10.15829/29/1560–4071–2020–4076

20. Mach F., Baigent C., Catapano A. L., Koskinas K. C., Casula M., Badimon L., Chapman M. J., De Backer G. G., Delgado V., Ference B. A., Graham I. M., Halliday A., Landmesser U., Mihaylova B., Pedersen T. R., Riccardi G., Richter D. J., Sabatine M. S., Taskinen M. R., Tokgozoglu L., Wiklund O.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111188. https://doi.org/10.1093/eurheartj/ehz455

21. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344 (8934): 1383–9. https://pubmed.ncbi.nlm.nih.gov/7968073/

22. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Russian Journal of Cardiology. 2018; (8): 164–221. (In Russ.) https://doi.org/10.15829/1560–4071–2018–8–164–221

23. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37 (39): 29993058. https://doi.org/10.1093/eurheartj/ehw272

24. Aung P. P., Maxwell H. G., Jepson R. G., Price J. F., Leng G. C. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007; 2007 (4): CD 000123. https://doi.org/10.1002/14651858.CD000123.pub2

25. Kumbhani D. J., Steg P. G., Cannon C. P., Eagle K. A., Smith S. C. Jr, Goto S., Ohman E. M., Elbez Y., Sritara P., Baumgartner I., Banerjee S., Creager M. A., Bhatt D. L. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35 (41): 2864–2872. https://doi.org/10.1093/eurheartj/ehu080.

26. Amarenco P., Labreuche J., Lavallée P., Touboul P. J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004; 35 (12): 2902–9. https://doi.org/10.1161/01.STR.0000147965.52712.fa.

27. Harker L. A., Boissel J. P., Pilgrim A. J., Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999; 21 (4): 325–35. https://doi.org/10.2165/00002018–199921040–00007.

28. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348 (9038): 1329 39. https://doi.org/10.1016/S0140–6736(96)09457–3

29. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002; 324 (7329): 71–86. https://doi.org/10.1136/bmj.324.7329.71. Erratum in: BMJ 2002 Jan 19; 324 (7330): 141.

30. Sacco R. L., Diener H. C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A, Palesch Y., Martin R. H., Albers G. W., Bath P., Bornstein N., Chan B. P., Chen S. T., Cunha L., Dahlöf B., De Keyser J., Donnan G. A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., Vandermaelen C., Voigt T., Weber M., Yoon B. W.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008; 359 (12): 1238–51. https://doi.org/10.1056/NEJMoa0805002

31. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348 (9038): 1329–1339. https://doi.org/10.1016/s0140–6736(96)09457–3

32. Hiatt W. R., Fowkes F. G., Heizer G., Berger J.S, Baumgartner I., Held P., Katona B. G., Mahaffey K. W., Norgren L., Jones W. S., Blomster J., Millegård M., Reist C., Patel M. R.; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017; 376 (1): 32–40. https://doi.org/10.1056/NEJMoa1611688.

33. Clinical practice guidelines Atrial fibrillation and flutter 2020 (In Russ.) https://webmed.irkutsk.ru/doc/pdf/fedaf.pdf. Date accessed: 15.03.2021.

34. Mant J. W., Richards S. H., Hobbs F. D., Fitzmaurice D., Lip G. Y., Murray E., Banting M., Fletcher K., Rahman J., Allan T., Raftery J., Bryan S.; Midlands Research Consortium of General Practice. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomized controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN 89345269]. BMC Cardiovasc Disord. 2003; (3): 9. https://doi.org/10.1186/1471–2261–3–9

35. Medicare Amin A., Keshishian A., Dina O., Dhamane A., Nadkarni A., Carda E., Russ C., Rosenblatt L., Mardekian J., Yuce H., Baker C. L. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis. 2019; 48 (2): 240–249. https://doi.org/10.1007/s11239–019–01838–5

36. Kanis J. A., on behalf of the who scientific group. Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield (UK): University of Sheffield (UK), Who Collaboraiting Centre; 2007. https://www.who.int/chp/topics/Osteoporosis.pdf. Date accessed: 15.03.2021.

37. Clinical guidelines Osteoporosis 2016 (In Russ.) https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_osteoporosis_2016.pdf. Date accessed:15.03.2021.

38. Mel’nichenko G.A., Belaya Z. E., Rozhinskaya L. Y., Toroptsova N. V., Alekseeva L. I., Biryukova E. V., Grebennikova T. A., Dzeranova L. K., Dreval A. V., Zagorodniy N. V., Il’yin A.V., Kryukova I. V., Lesnyak O. M., Mamedova E. O., Nikitinskaya O. A., Pigarova E. A., Rodionova S. S., Skripnikova I. A., Tarbaeva N. V., Farba L. Y., Tsoriev T. T., Chernova T. O., Yureneva S. V., Yakushevskaya O. V., Dedov I. I. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2017; 63 (6): 392–426. (In Russ.) https://doi.org/10.14341/probl2017636392–426.

39. Dedov I. I., Melnichenko G. A., Belaya Zh.E., Rozhinskaya L. Ya. Osteoporosis – from a rare symptom of endocrine diseases to a silent epidemic of the XX–XXI century. Endocrinology problems. 2011; 57 (1): 35–45. (In Russ.)

40. Black D. M., Delmas P. D., Eastell R., Reid I. R., Boonen S., Cauley J. A., Cosman F., Lakatos P., Leung P. C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T. F., Sellmeyer D., Eriksen E. F., Cummings S. R.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809–1822. https://doi.org/10.1056/NEJMoa067312

41. Boonen S., Reginster J. Y., Kaufman J. M., Lippuner K., Zanchetta J., Langdahl B., Rizzoli R., Lipschitz S., Dimai H. P., Witvrouw R., Eriksen E., Brixen K., Russo L., Claessens F., Papanastasiou P., Antunez O., Su G., Bucci-Rechtweg C., Hruska J., Incera E., Vanderschueren D., Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367 (18): 1714–1723. https://doi.org/10.1056/NEJMoa1204061

42. Reid D. M., Devogelaer J. P., Saag K., Roux C., Lau C. S., Reginster J. Y., Papanastasiou P., Ferreira A., Hartl F., Fashola T., Mesenbrink P., Sambrook P. N.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373 (9671): 1253–1263. https://doi.org/10.1016/S0140–6736(09)60250–6

43. Black D. M., Cummings S. R., Karpf D. B., Cauley J. A., Thompson D. E., Nevitt M. C., Bauer D. C., Genant H. K., Haskell W. L., Marcus R., Ott S. M., Torner J. C., Quandt S. A., Reiss T. F., Ensrud K. E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348 (9041): 1535–1541. https://doi.org/10.1016/s0140–6736(96)07088–2

44. Harris S. T., Blumentals W. A., Miller P. D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008; 24 (1): 237–245. https://doi.org/10.1185/030079908x253717

45. Langdahl B. L., Teglbjærg C. S., Ho P. R., Chapurlat R., Czerwinski E., Kendler D. L., Reginster J. Y., Kivitz A., Lewiecki E. M., Miller P. D., Bolognese M. A., McClung M.R., Bone H. G., Ljunggren Ö., Abrahamsen B., Gruntmanis U., Yang Y. C., Wagman R. B., Mirza F., Siddhanti S., Orwoll E. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015; 100 (4): 1335–1342. https://doi.org/10.1210/jc.2014–4079

46. Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int. 2008; 82(2): 102–107. https://doi.org/10.1007/s00223–008–9102–0

47. Pigarova E. A., Rozhinskaya L. Y., Belaya J. E., Dzeranova L. K., Karonova T. L., Ilyin A. V., Melnichenko G. A., Dedov I. I. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016; 62 (4): 60–84. (In Russ.) https://doi.org/10.14341/probl201662460–84

48. Chemical composition of food products used in the Russian Federation (In Russ.) http://web.ion.ru/food/FD_tree_grid.aspx. Date accessed:15.03.2021.

49. Boonen S., Bischoff-Ferrari H.A., Cooper C., Lips P., Ljunggren O., Meunier P. J., Reginster J. Y. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int. 2006; 78 (5): 257–270. https://doi.org/10.1007/s00223–005–0009–8